Dimensional Fund Advisors
KNTE

Dimensional Fund Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Dimensional Fund Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-91,961
Closed -$245K – 3447
2024
Q1 		$245K Buy
91,961
+77,368
+530% +$192K ﹤0.01% 3164
2023
Q4 		$34.7K Buy
14,593
+2,344
+19% +$4.15K ﹤0.01% 3370
2023
Q3 		$17.1K Sell
12,249
-13,335
-52% -$32K ﹤0.01% 3448
2023
Q2 		$77.8K Sell
25,584
-6,962
-21% -$26.8K ﹤0.01% 3360
2023
Q1 		$203K Sell
32,546
-5,852
-15% -$35.7K ﹤0.01% 3198
2022
Q4 		$234 Sell
38,398
-510
-1% -$4.15K ﹤0.01% 3197
2022
Q3 		$465K Buy
38,908
+7,515
+24% +$98.4K ﹤0.01% 3062
2022
Q2 		$396K Buy
+31,393
New +$292K ﹤0.01% 3114

Dimensional Fund Advisors's KNTE Position: Q2 2024 in Review

Dimensional Fund Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 91,961 shares — an estimated $245K sold.

Dimensional Fund Advisors first reported a position in KNTE in Q2 2022 and held it in 8 quarters. The position peaked at $465K in Q3 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Dimensional Fund Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 91,961 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $245K.
  • Dimensional Fund Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 8 quarters.
  • Dimensional Fund Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $465K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.